Rubella virus envelope glycoproteins (E1 and E2) (RUBV E1/E2)

The Rubella virus surface proteins, primarily the E1 and E2 glycoproteins, are essential structural components of the viral envelope that mediate host cell entry and assembly (UniProt: P03310). E1 is the major surface antigen and a class II viral fusion protein responsible for receptor binding and low-pH-triggered membrane fusion, while E2 functions as a chaperone for E1 transport and is also a target for neutralizing antibodies (PubMed: 16188213). These proteins are the primary targets for the protective immune response induced by the live-attenuated Rubella vaccine (RA 27/3 strain), which has been instrumental in reducing the incidence of Rubella and the devastating Congenital Rubella Syndrome (StatPearls: NBK559100). In therapeutic development, these glycoproteins are the focus of neutralizing monoclonal antibody research aimed at providing passive immunity or treating chronic rubella-associated conditions (PubMed: 30108163).

Other names

E1 glycoproteinE2 glycoproteinRubella virus spike proteinsRUBV envelope proteinsStructural polyprotein (cleavage products)

Vaccines targeting these proteins induce the production of neutralizing antibodies, primarily against the E1 glycoprotein, which block viral attachment to host receptors and inhibit the conformational changes required for membrane fusion (CDC: Rubella Vaccination; PubMed: 16188213).